<DOC>
	<DOCNO>NCT00003430</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness L-778,123 treating patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>L-778,123 Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose L-778,123 patient recurrent refractory solid tumor . II . Evaluate safety tolerability L-778,123 include qualitative , quantitative , dose limit toxicity patient . III . Assess pharmacokinetic profile regimen patient . IV . Evaluate radiologic tumor marker response treatment patient . V. Evaluate relationship ras mutation response treatment patient . VI . Determine relationship plasma drug level farnesylation assay result . OUTLINE : This dose escalation study . Patients receive continuous infusion L-778,123 7 day every 3 week . Treatment continue absence disease progression unacceptable toxic effect . All patient observe least 1 week 7 day infusion L-778,123 prior subsequent dose escalation . Cohorts 3-6 patient receive escalate dos L-778,123 maximum tolerate dose ( MTD ) reach . MTD define dose 2 6 patient experience dose limit toxicity . Patients follow death . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory solid tumor include , limited : Pancreatic cancer Bladder cancer Colon cancer Head neck cancer Lung cancer Measurable disease measurable tumor marker ( base solely cytopathological data ) No primary active metastatic CNS disease ( assessed edema 2 radiologic image technique least 4 week apart ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm3 PT PTT great 1.2 time upper limit normal ( ULN ) Hepatic : Bilirubin great 1.5 time ULN ALT AST great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No grade 3 cardiac dysrhythmias No atrial fibrillation No prior myocardial infarction No history unstable angina No history congestive heart failure LVEF great 50 % patient prior cumulative anthracycline dose le 450 mg/m2 doxorubicin Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception least 2 week , throughout , least 2 week study Permanent central venous catheter place No history illicit drug alcohol abuse within past 5 year No emotional psychiatric disorder No known significant drug allergy serious adverse experience market investigational drug No allergy latex Normal serum electrolytes No serious medical disorder No active infection No history significant retinal disorder disease No history seizure disorder PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunologic therapy No concurrent immunologic therapy Chemotherapy : At least 4 week since prior chemotherapy At least 6 week since prior mitomycin nitrosoureas No prior high dose chemotherapy stem cell rescue No concurrent chemotherapy No prior anthracycline dose exceed equivalent great 45O mg/m2 doxorubicin Endocrine therapy : At least 4 week since prior endocrine therapy ( include steroid ) No concurrent endocrine therapy Radiotherapy : At least 4 week since prior radiotherapy No prior radiation great 25 % total bone marrow No concurrent radiotherapy Surgery : At least 4 week since prior surgery No concurrent surgery Other : At least 30 day since prior investigational agent No concurrent medication dysrhythmic potential include , limited : terfenadine , astemizole , cisapride , diphenhydramine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , tricyclic antidepressant , haloperidol , risperidone , indapamine No concurrent rifampin , phenobarbital , phenytoin , inducer CYP3A No concurrent triazolam , alprazolam , midazolam , CYP3A metabolize benzodiazepine No concurrent HMGCoA reductase inhibitor ( except fluvastatin ) No concurrent anticoagulant therapy ( low dose warfarin therapy maintain catheter patency allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
</DOC>